Application of 1 beta-hydroxy alantolactone in preparation of medicine for preventing and curing rheumatoid arthritis

A technology of inulin and arthritis, which is applied in the application field of medicine, and can solve problems such as inflammation and sequelae treatment stage

Inactive Publication Date: 2012-06-20
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF5 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no specific therapy for rheumatoid arthritis so far, and it is still in the treatment stage of inflammation and sequelae.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 1 beta-hydroxy alantolactone in preparation of medicine for preventing and curing rheumatoid arthritis
  • Application of 1 beta-hydroxy alantolactone in preparation of medicine for preventing and curing rheumatoid arthritis
  • Application of 1 beta-hydroxy alantolactone in preparation of medicine for preventing and curing rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 Preparation of 1β-hydroxy inulin

[0021]10.0kg of dry inula (I.japonica) aerial parts (including stems, leaves and flowers collected from Haozhou, Anhui) were pulverized and extracted 3 times with 95% ethanol at room temperature (temperature 25° C.) 100L), each time is 24, 12, 12 hours respectively. After diluting 427.5 g of the obtained crude extract with an appropriate amount (10 L) of water, dilute with petroleum ether (divided into four times, each 40 L), dichloromethane (divided into four times, each 40 L), ethyl acetate (divided into four times, each 40 L) , each 40L), n-butanol extraction (four times, each 40L). 50.5 g of the dichloromethane extract obtained therein was separated with 200-300 mesh thin-layer silica gel, and dichloromethane-methanol (100:0, 50:1, 20:1, 10:1, 5:1, 2: 1,) carry out gradient elution. Thin-layer chromatography detection (2010 editions Chinese Pharmacopoeia Appendix VI B thin-layer chromatography), collects the component ...

Embodiment 21

[0022] Example 21 Beta-Hydroxy Inulin Animal Drug Efficacy Test

[0023] 1. Experimental materials

[0024] Drugs and Reagents

[0025] 1β-hydroxy inulin: prepared in Example 1, dissolved in a 3‰ CMC-Na (sodium carboxymethylcellulose) solution to a 1 mg / ml solution. Different volumes were intraperitoneally injected according to the body weight of the animals.

[0026] Chicken type II collagen (C II): Chondrex, Redmond, WA 98052, USA;

[0027] Incomplete Freund's Adjuvant (IFA) Difco Laboratories, Detroit, MI;

[0028] Phosphate Buffered Saline (PBS): Prepared by our laboratory: Dissolve 8gNaCl, 0.2g KCl, 1.44g NaCl in 800ml distilled water 2 HPO 4 and 0.24g KH 2 PO 4 . Adjust the pH to 7.4 with hydrochloric acid, add water to make up to 1L, filter and sterilize before use;

[0029] DMSO dimethyl sulfoxide (Dimethyl sulfoxide, DMSO): a product of sigma;

[0030] 1640 Medium: Gino Biomedical Technology Co., Ltd.;

[0031] Calf serum: Minhai Biological Co., Ltd.;

[0...

Embodiment 3

[0066] tablet:

[0067] Preparation method: mix 1β-hydroxy inulin, lactose and starch, moisten evenly with water, sieve the wetted mixture and dry it, then sieve it, add magnesium stearate, then press the mixture into tablets, each tablet weighs 300mg, 1β-hydroxy inulin content is 25mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of 1 beta-hydroxy alantolactone in preparation of medicine for preventing and curing rheumatoid arthritis. The structural formula of the 1 beta-hydroxy alantolactone is as follows: the 1 beta-hydroxy alantolactone is used for carrying out animal pharmaceutical effect tests, and results show that the 1 beta-hydroxy alantolactone obviously suppresses attack severity and morbidity of CIA (collagen-induced arthritis). TNF-alpha (tumor necrosis factors alpha), IL-17 (interleukin 17) and IFN-gamma (interferon gamma) in supernate of splenocyte can be reduced, secretion of proinflammatory cytokine TNF-alpha, IFN-gamma and IL-17 is suppressed, and accordingly CIA diseases are prevented. Accordingly, the application can be used for preparing medicine for treating rheumatoid arthritis. Medicine composition in the invention is prepared by the 1 beta-hydroxy alantolactone used as active ingredients and conventional medicine carriers and can be prepared into tablets, dispersible tablets, lozenge, orally disintegrating tablets, sustained-release tablets, capsules, soft capsules, dropping pills, granular formulation, injection, powder injection or aerosol and the like. The application has great clinical application values.

Description

technical field [0001] The invention relates to traditional Chinese medicines, in particular to the application of 1β-hydroxy inulin in the preparation of medicines for preventing and treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (Rheumatoid Arthritis, RA) is a chronic systemic inflammatory disease of unknown etiology, with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations, belonging to autoimmune inflammatory diseases disease. The disease is prone to occur in small joints such as hands, wrists, and feet, and is easy to recur, and is symmetrically distributed. In the early stage of the disease, joints are red, swollen, hot, painful, and dysfunctional. In the late stage, the joints may appear stiff and deformed in varying degrees, accompanied by atrophy of bones and skeletal muscles, and are easily disabled. From the perspective of pathological changes, rheumatoid arthritis is a d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P19/02A61P29/00
CPCA61K31/365A61K9/0053A61P19/02A61P29/00
Inventor 张卫东胡振林苏娟单磊柳润辉李慧梁徐希科
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap